Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012 (2012), Article ID 629452, 10 pages
http://dx.doi.org/10.1155/2012/629452
Review Article

Therapeutic Interventions against Inflammatory and Angiogenic Mediators in Proliferative Diabetic Retinopathy

Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02131, USA

Received 11 July 2012; Accepted 15 August 2012

Academic Editor: Mario R. Romano

Copyright © 2012 Daniel Gologorsky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. D. R. Whiting, L. Guariguata, C. Weil, and J. Shaw, “IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030,” Diabetes Research and Clinical Practice, vol. 94, no. 3, pp. 311–321, 2011. View at Google Scholar
  3. C. Gustavsson, C. D. Agardh, and E. Agardh, “Profile of intraocular tumour necrosis factor-alpha and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy,” Acta Ophthalmologica, http://www.ncbi.nlm.nih.gov/pubmed/22520269. In press. View at Publisher · View at Google Scholar
  4. A. P. Adamis, “Is diabetic retinopathy an inflammatory disease?” British Journal of Ophthalmology, vol. 86, no. 4, pp. 363–365, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Shamoon, H. Duffy, N. Fleischer et al., “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Turner, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Brownlee, “The pathobiology of diabetic complications: a unifying mechanism,” Diabetes, vol. 54, no. 6, pp. 1615–1625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Rangasamy, P. G. McGuire, and A. Das, “Diabetic retinopathy and inflammation: novel therapeutic targets,” Middle East African Journal of Ophthalmology, vol. 19, no. 1, pp. 52–59, 2012. View at Google Scholar
  9. L. M. Aiello and J. Cavallerano, “Diabetic retinopathy,” Current therapy in Endocrinology and Metabolism, vol. 5, pp. 436–446, 1994. View at Google Scholar · View at Scopus
  10. D. S. Fong, L. Aiello, T. W. Gardner et al., “Diabetic retinopathy,” Diabetes Care, vol. 26, no. 1, pp. 226–229, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. E. U. Powell and R. Field, “Diabetic retinopathy and rheumatoid arthritis,” The Lancet, vol. 284, no. 7349, pp. 17–18, 1964. View at Google Scholar · View at Scopus
  12. K. Miyamoto, S. Khosrof, S. E. Bursell et al., “Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 19, pp. 10836–10841, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Schroder, W. Palinski, and G. W. Schmid-Schonbein, “Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy,” The American Journal of Pathology, vol. 139, no. 1, pp. 81–100, 1991. View at Google Scholar · View at Scopus
  14. F. C. Barouch, K. Miyamoto, J. R. Allport et al., “Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes,” Investigative Ophthalmology and Visual Science, vol. 41, no. 5, pp. 1153–1158, 2000. View at Google Scholar · View at Scopus
  15. K. M. K. Rao, D. L. Hatchell, H. J. Cohen, and M. A. De la Paz, “Alterations in stimulus-induced integrin expression in peripheral blood neutrophils of patients with diabetic retinopathy,” American Journal of the Medical Sciences, vol. 313, no. 3, pp. 131–137, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Olson, C. M. Whitelaw, K. C. McHardy, D. W. M. Pearson, and J. V. Forrester, “Soluble leucocyte adhesion molecules in diabetic retinopathy stimulate retinal capillary endothelial cell migration,” Diabetologia, vol. 40, no. 10, pp. 1166–1171, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Usui, S. Ishida, K. Yamashiro et al., “VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2,” Investigative Ophthalmology and Visual Science, vol. 45, no. 2, pp. 368–374, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. G. S. Robinson, E. A. Pierce, S. L. Rook, E. Foley, R. Webb, and L. E. H. Smith, “Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 10, pp. 4851–4856, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. M. J. Tolentino, D. S. McLeod, M. Taomoto, T. Otsuji, A. P. Adamis, and G. A. Lutty, “Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate,” American Journal of Ophthalmology, vol. 133, no. 3, pp. 373–385, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Lu, V. L. Perez, N. Ma et al., “VEGF increases retinal vascular ICAM-1 expression in vivo,” Investigative Ophthalmology and Visual Science, vol. 40, no. 8, pp. 1808–1812, 1999. View at Google Scholar · View at Scopus
  23. A. M. Joussen, V. Poulaki, W. Qin et al., “Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo,” The American Journal of Pathology, vol. 160, no. 2, pp. 501–509, 2002. View at Google Scholar · View at Scopus
  24. M. Waisbourd, M. Goldstein, and A. Loewenstein, “Treatment of diabetic retinopathy with anti-VEGF drugs,” Acta Ophthalmologica, vol. 89, no. 3, pp. 203–207, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 3, pp. 363–372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Mirshahi, R. Roohipoor, A. Lashay, S. F. Mohammadi, A. Abdoallahi, and H. Faghihi, “Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial,” European Journal of Ophthalmology, vol. 18, no. 2, pp. 263–269, 2008. View at Google Scholar · View at Scopus
  27. G. Schmidinger, N. Maar, M. Bolz, C. Scholda, and U. Schmidt-Erfurth, “Repeated intravitreal bevacizumab (AvastinÂ) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation,” Acta Ophthalmologica, vol. 89, no. 1, pp. 76–81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. B. P. Nicholson and A. P. Schachat, “A review of clinical trials of anti-VEGF agents for diabetic retinopathy,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 248, no. 7, pp. 915–930, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. J. M. Rosenstein, N. Mani, W. F. Silverman, and J. M. Krum, “Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 12, pp. 7086–7091, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Hayashi, K. Abe, and Y. Itoyama, “Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia,” Journal of Cerebral Blood Flow and Metabolism, vol. 18, no. 8, pp. 887–895, 1998. View at Google Scholar · View at Scopus
  31. Z. G. Zhang, L. Zhang, Q. Jiang et al., “VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain,” Journal of Clinical Investigation, vol. 106, no. 7, pp. 829–838, 2000. View at Google Scholar · View at Scopus
  32. Y. Sun, K. Jin, L. Xie et al., “VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia,” Journal of Clinical Investigation, vol. 111, no. 12, pp. 1843–1851, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Vezzani, “VEGF as a target for neuroprotection,” Epilepsy Currents/American Epilepsy Society, vol. 8, no. 5, pp. 135–137, 2008. View at Google Scholar
  34. J. N. Nicoletti, S. K. Shah, D. P. McCloskey et al., “Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus,” Neuroscience, vol. 151, no. 1, pp. 232–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. P. A. D'Amore, “Vascular endothelial cell growth factor-A: not just for endothelial cells anymore,” American Journal of Pathology, vol. 171, no. 1, pp. 14–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Nishijima, Y. S. Ng, L. Zhong et al., “Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury,” The American Journal of Pathology, vol. 171, no. 1, pp. 53–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. A. P. Adamis and A. J. Berman, “Immunological mechanisms in the pathogenesis of diabetic retinopathy,” Seminars in Immunopathology, vol. 30, no. 2, pp. 65–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. A. M. Joussen, V. Poulaki, M. L. Le et al., “A central role for inflammation in the pathogenesis of diabetic retinopathy,” The FASEB Journal, vol. 18, no. 12, pp. 1450–1452, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. D. S. McLeod, D. J. Lefer, C. Merges, and G. A. Lutty, “Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid,” The American Journal of Pathology, vol. 147, no. 3, pp. 642–653, 1995. View at Google Scholar · View at Scopus
  40. P. Esser, M. Bresgen, R. Fischbach, K. Heimann, and P. Wiedemann, “Intercellular adhesion molecule-1 levels in plasma and vitreous from patients with vitreoretinal disorders,” German Journal of Ophthalmology, vol. 4, no. 5, pp. 269–274, 1995. View at Google Scholar · View at Scopus
  41. J. Adamiec-Mroczek and J. Oficjalska-Młyńczak, “Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes—role of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 12, pp. 1665–1670, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. G. A. Limb, J. Hickman-Casey, R. D. Hollifield, and A. H. Chignell, “Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 40, no. 10, pp. 2453–2457, 1999. View at Google Scholar · View at Scopus
  43. G. R. Barile, S. Chang, L. Park, V. S. Reppucci, W. M. Schiff, and A. M. Schmidt, “Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy,” Current Eye Research, vol. 19, no. 3, pp. 219–227, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. A. M. Joussen, V. Poulaki, N. Mitsiades et al., “Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression,” The FASEB Journal, vol. 16, no. 3, pp. 438–440, 2002. View at Google Scholar · View at Scopus
  45. Y. Hirano, E. Sakurai, A. Matsubara, and Y. Ogura, “Suppression of ICAM-1 in retinal and choroidal endothelial cells by plasmid small-interfering RNAs in vivo,” Investigative Ophthalmology and Visual Science, vol. 51, no. 1, pp. 508–515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Arita, Y. Hata, S. Nakao et al., “Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage,” Diabetes, vol. 58, no. 1, pp. 215–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Yoshida, K. Ishikawa, R. Asato et al., “Increased expression of periostin in vitreous and fibrovascular membranes obtained from patients with proliferative diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 52, no. 8, pp. 5670–5678, 2011. View at Google Scholar
  48. S. G. Elner, V. M. Elner, Z. M. Bian et al., “Human retinal pigment epithelial cell interleukin-8 and monocyte chemotactic protein-1 modulation by T-lymphocyte products,” Investigative Ophthalmology and Visual Science, vol. 38, no. 2, pp. 446–455, 1997. View at Google Scholar · View at Scopus
  49. G. A. Limb, R. D. Hollifield, L. Webster, D. G. Charteris, and A. H. Chignell, “Soluble TNF receptors in vitreoretinal proliferative disease,” Investigative Ophthalmology and Visual Science, vol. 42, no. 7, pp. 1586–1591, 2001. View at Google Scholar · View at Scopus
  50. T. Yuuki, T. Kanda, Y. Kimura et al., “Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy,” Journal of Diabetes and its Complications, vol. 15, no. 5, pp. 257–259, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Adamiec-Mroczek, J. Oficjalska-Młyńczak, and M. Misiuk-Hojło, “Proliferative diabetic retinopathy-The influence of diabetes control on the activation of the intraocular molecule system,” Diabetes Research and Clinical Practice, vol. 84, no. 1, pp. 46–50, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Zhou, S. Wang, and X. Xia, “Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy,” Current eye Research, vol. 37, no. 5, pp. 416–420, 2012. View at Google Scholar
  53. C. Capeans, M. V. De Rojas, S. Lojo, and M. S. Salorio, “C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy,” Retina, vol. 18, no. 6, pp. 546–550, 1998. View at Google Scholar · View at Scopus
  54. A. Tashimo, Y. Mitamura, S. Nagai et al., “Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy,” Diabetic Medicine, vol. 21, no. 12, pp. 1292–1297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Pfeiffer, J. Spranger, R. Meyer-Schwickerath, and H. Schatz, “Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown,” Diabetes, vol. 46, supplement 2, pp. S26–S30, 1997. View at Google Scholar · View at Scopus
  56. J. I. Patel, P. G. Hykin, Z. J. Gregor, M. Boulton, and I. A. Cree, “Angiopoietin concentrations in diabetic retinopathy,” British Journal of Ophthalmology, vol. 89, no. 4, pp. 480–483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Rangasamy, R. Srinivasan, J. Maestas, P. G. McGuire, and A. Das, “A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 52, no. 6, pp. 3784–3791.
  58. U. Fiedler, Y. Reiss, M. Scharpfenecker et al., “Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation,” Nature Medicine, vol. 12, no. 2, pp. 235–239, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. W. C. Parks, C. L. Wilson, and Y. S. López-Boado, “Matrix metalloproteinases as modulators of inflammation and innate immunity,” Nature Reviews Immunology, vol. 4, no. 8, pp. 617–629, 2004. View at Google Scholar · View at Scopus
  60. S. J. Giebel, G. Menicucci, P. G. McGuire, and A. Das, “Matrix metalloproteinases in early diabetic retinopathy and their role in alternation of the blood-retinal barrier,” Laboratory Investigation, vol. 85, no. 5, pp. 597–607, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Jin, K. Kashiwagi, Y. Iizuka, Y. Tanaka, M. Imai, and S. Tsukahara, “Matrix metalloproteinases in human diabetic and nondiabetic vitreous,” Retina, vol. 21, no. 1, pp. 28–33, 2001. View at Google Scholar · View at Scopus
  62. D. Navaratna, P. G. McGuire, G. Menicucci, and A. Das, “Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes,” Diabetes, vol. 56, no. 9, pp. 2380–2387, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. A. J. Augustin, W. Breipohl, T. Boker, J. Lutz, and M. Spitznas, “Increased lipid peroxide levels and myeloperoxidase activity in the vitreous of patients suffering from proliferative diabetic retinopathy,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 231, no. 11, pp. 647–650, 1993. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Geraldes, J. Hiraoka-Yamamoto, M. Matsumoto et al., “Activation of PKC-and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy,” Nature Medicine, vol. 15, no. 11, pp. 1298–1306, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Ishii, M. R. Jirousek, D. Koya et al., “Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor,” Science, vol. 272, no. 5262, pp. 728–731, 1996. View at Google Scholar · View at Scopus
  66. L. P. Aiello, “The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial,” Diabetes, vol. 54, no. 7, pp. 2188–2197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. L. P. Aiello, M. D. Davis, A. Girach et al., “Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy,” Ophthalmology, vol. 113, no. 12, pp. 2221–2230, 2006. View at Google Scholar
  68. P. M. Titchenell, C. M. Lin, J. M. Keil, J. M. Sundstrom, C. D. Smith, and D. A. Antonetti, “Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction,” The Biochemical Journal, vol. 446, no. 3, pp. 455–467, 2012. View at Google Scholar
  69. D. Pathak, A. Gupta, B. Kamble, G. Kuppusamy, and B. Suresh, “Oral targeting of protein kinase C receptor: promising route for diabetic retinopathy?” Current Drug Delivery, vol. 9, no. 4, pp. 405–413, 2012. View at Google Scholar
  70. R. N. Frank, “Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors,” American Journal of Ophthalmology, vol. 133, no. 5, pp. 693–698, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. M. I. L. Gálvez, “Rubosixtaurin and other pkc inhibitors in diabetic retinopathy and macular Edema. Review,” Current Diabetes Reviews, vol. 5, no. 1, pp. 14–17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. L. P. Aiello, “The potential role of PKC β in diabetic retinopathy and macular edema,” Survey of Ophthalmology, vol. 47, supplement 2, pp. S263–S269, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. S. G. Lee, J. L. Kim, H. K. Lee et al., “Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 3, pp. 389–397, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Keech, P. Mitchell, P. Summanen et al., “Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial,” The Lancet, vol. 370, no. 9600, pp. 1687–1697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Y. Chew, W. T. Ambrosius, M. D. Davis et al., “Effects of medical therapies on retinopathy progression in type 2 diabetes,” The New England Journal of Medicine, vol. 363, no. 3, pp. 233–244, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Y. Wong, R. Simo, and P. Mitchell, “Fenofibrate—a potential systemic treatment for diabetic retinopathy?” American Journal of Ophthalmology, vol. 154, no. 1, pp. 6–12, 2012. View at Google Scholar
  77. A. D. Wright and P. M. Dodson, “Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies,” Eye, vol. 25, no. 7, pp. 843–849, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. P. M. Ridker, E. Danielson, F. A. H. Fonseca et al., “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein,” The New England Journal of Medicine, vol. 359, no. 21, pp. 2195–2207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. P. M. Ridker, A. Pradhan, J. G. MacFadyen et al., “Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial,” The Lancet, vol. 380, no. 9841, pp. 565–571, 2012. View at Google Scholar
  80. UK Prospective Diabetes Study Group, “Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38,” British Medical Journal, vol. 317, no. 7160, pp. 703–713, 1999. View at Google Scholar · View at Scopus
  81. A. Patel, S. MacMahon, J. Chalmers et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. J. W. J. Beulens, A. Patel, J. R. Vingerling et al., “Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial,” Diabetologia, vol. 52, no. 10, pp. 2027–2036, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Bucolo, K. W. Ward, E. Mazzon, S. Cuzzocrea, and F. Drago, “Protective effects of a coumarin derivative in diabetic rats,” Investigative Ophthalmology and Visual Science, vol. 50, no. 8, pp. 3846–3852, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Cuzzocrea, E. Mazzon, C. Bevilaqua et al., “Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats,” British Journal of Pharmacology, vol. 131, no. 7, pp. 1399–1407, 2000. View at Google Scholar · View at Scopus
  85. M. C. Thomas, J. W. Baynes, S. R. Thorpe, and M. E. Cooper, “The role of AGEs and AGE inhibitors in diabetic cardiovascular disease,” Current Drug Targets, vol. 6, no. 4, pp. 453–474, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Zong, M. Ward, and A. W. Stitt, “AGEs, RAGE, and diabetic retinopathy,” Current Diabetes Reports, vol. 11, no. 4, pp. 244–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Li, J. Tang, Y. Du, C. A. Lee, and T. S. Kern, “Beneficial effects of a novel RAGE inhibitor on early diabetic retinopathy and tactile allodynia,” Molecular Vision, vol. 17, pp. 3156–3165, 2011. View at Google Scholar